Start the conversation
Here at Private Briefing, we were able to finish out 2013 in a big way.
And that points to a hot start in 2014.
Two more recommendations made the Private Briefing "double-or-better" list - meaning they've risen at least 100%. Analysts now think there's more room to run.
And Zacks Equity Research says one of our hottest recent performers - a sub-$5-a-share biotech - still likely has room to zoom.
This is premium content for Private Briefing subscribers only.